Table of Contents 1. Report scope & Methodology 1.1 Scope of the Report 1.2 Research Methodology 1.3 Executive Summary 2. Strategic Recommendations 2.1 Both Healthcare Providers and Public Health Agencies to Improve Diagnostics 2.2 Escalate the awareness among the population of APAC region 3. Global Invasive Fungal Infection Product Outlook 4. Global Invasive Fungal Infection Market: Sizing, Growth, Forecast 4.1 Market Size, By Value, Year 2014-2024 5. Global Invasive Fungal Infection Market Segmentation By Diseases 5.1 Competitive Scenario of Global Invasive Fungal Infection Market: By Diseases 5.2 Candidaemia and invasive candiasis – Market Size and Forecast (2019-2024) 5.3 Intra-abdominal Candiasis (Candida Peritonitis) - Market Size and Forecast (2019-2024) 5.4 Cryptococcal Meningitis – Market Size and Forecast (2019-2024) 5.5 Histoplasmosis Disseminated- Market Size and Forecast (2019-2024) 5.6 Histoplasmosis acute pulmonary – Market Size and Forecast (2019-2024) 5.7 Invasive Aspergillosis - Market Size and Forecast (2019-2024) 5.8 Invasive Rhinosinusitis – Market Size and Forecast (2019-2024) 5.9 Mucormycosis - Market Size and Forecast (2019-2024) 5.10 Pneumocystis Pneumonia - Market Size and Forecast (2019-2024) 5.11 Others – Market Size and Forecast (2019-2024) 6. Global Invasive Fungal Infection Market: Regional Analysis 6.1 Competitive Scenario of Global Invasive Fungal Infection: By Region 7. North America Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024) 7.1 North America Invasive Fungal Infection Market: Size and Forecast (2019-2024) 7.2 North America Invasive Fungal Infection Market – Prominent Companies 7.3 Market Segmentation By Product Type- (Diseases) 7.4 Market Segmentation By Diseases (Candidemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others) 7.5 North America Invasive Fungal Infection Market: Country Analysis 7.6 Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024) 7.7 Competitive Scenario of North America Invasive Fungal Infection: By Country 7.8 United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) 7.9 United States Invasive Fungal Infection Market Segmentation- By Diseases 7.10 Canada Invasive Fungal Infection Market: Size and Forecast (2019-2024) 7.11 Canada Invasive Fungal Infection Market Segmentation- By Diseases 8. Europe Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024) 8.1 Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value (Year-2024) 8.2 Competitive Scenario of Europe Invasive Fungal Infection: By Country 8.3 Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.4 Europe Invasive Fungal Infection Market – Prominent Companies 8.5 Market Segmentation By Diseases- (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others) 8.6 Europe Invasive Fungal Infection Market: Country Analysis 8.7 Germany Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.8 Germany Invasive Fungal Infection Market Segmentation- By Diseases 8.9 France Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.10 France Invasive Fungal Infection Market Segmentation- By Diseases 8.11 United Kingdom Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.12 United Kingdom Invasive Fungal Infection Market Segmentation- By Diseases 8.13 Spain Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.14 Spain Invasive Fungal Infection Market Segmentation- By Diseases 8.15 Rest of Europe Invasive Fungal Infection Market: Size and Forecast (2019-2024) 8.16 Rest of Europe Invasive Fungal Infection Market Segmentation- By Product Type, End User 9. Asia Pacific Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024) 9.1 Market Opportunity Chart of Asia Pacific Invasive Fungal Infection Market - By Country, By Value (Year-2024) 9.2 Competitive Scenario of Asia Pacific Invasive Fungal Infection: By Country 9.3 Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.4 Asia Pacific Invasive Fungal Infection Market – Prominent Companies 9.5 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others) 9.6 Asia Pacific Invasive Fungal Infection Market: Country Analysis 9.7 China Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.8 China Invasive Fungal Infection Market Segmentation- By Diseases 9.9 South Korea Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.10 South Korea Invasive Fungal Infection Market Segmentation- By Diseases 9.11 Japan Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.12 Japan Invasive Fungal Infection Market Segmentation- By Diseases 9.13 India Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.14 India Invasive Fungal Infection Market Segmentation- By Diseases 9.15 Rest of Asia Pacific Invasive Fungal Infection Market: Size and Forecast (2019-2024) 9.16 Rest of Asia Pacific Invasive Fungal Infection Market Segmentation- By Diseases 10. Rest of the World Invasive Fungal Infection Market: Segmentation By Diseases (2019-2024) 10.1 Market Opportunity Chart of Rest of the World Invasive Fungal Infection Market - By Country, By Value (Year-2024) 10.2 Competitive Scenario of Rest of the World Invasive Fungal Infection: By Country 10.3 Rest of the World Invasive Fungal Infection Market: Size and Forecast (2019-2024) 10.4 Market Segmentation By Diseases (Candidaemia and invasive candiasis, Intra-abdominal Candiasis (Candida Peritonitis), Cryptococcal Meningitis , Histoplasmosis Disseminated, Histoplasmosis acute Pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others) 10.5 Rest of the World Invasive Fungal Infection Market: Country Analysis 10.6 Brazil Invasive Fungal Infection Market: Size and Forecast (2019-2024) 10.7 Brazil Invasive Fungal Infection Market Segmentation- By Diseases 10.8 Egypt Invasive Fungal Infection Market: Size and Forecast (2019-2024) 10.9 Egypt Invasive Fungal Infection Market Segmentation- By Diseases 10.10 Rest of the Countries Invasive Fungal Infection Market: Size and Forecast (2019-2024) 10.11 Rest of the Countries Invasive Fungal Infection Market Segmentation- By Diseases 11. Global Invasive Fungal Infection Market Dynamics 11.1 Global Invasive Fungal Infection Market Drivers 11.2 Global Invasive Fungal Infection Market Restraints 11.3 Global Invasive Fungal Infection Market Trends 12. Pipeline Drugs Analysis - Invasive Fungal Infection 13. Market Attractiveness and Strategic Analysis 13.1.1 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases(Year 2024) 13.1.2 Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Region (Year 2024) 14. Competitive Landscape 14.1 Market Share Analysis 14.2 SWOT Analysis 14.3 Porter’s Five Force Analysis 15. Company Analysis (Business Description, Financial Analysis, Business Strategy) 15.1 Cidara Therapeutics 15.2 Basilea Pharmaceutica 15.3 Pfizer 15.4 GlaxoSmithKline 15.5 Bayer AG 15.6 Abbott 15.7 Merck & Co 15.8 Astellas Pharma Inc. 15.9 F2G- the Rare Fungal Disease Company 15.10 Scynexis Inc.

List of Figures Figure 1: Global Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 2: Global Prevalence of HIV, (%), 2013–2017 Figure 3: Global Deaths by HIV, (%), 2013–2017 Figure 4: Global Prevalence of Neoplasms (%), 2014–2016 Figure 5: Global Prevalence of Tuberculosis (%), 2015–2017 Figure 6: Competitive Scenario of Global Fungal Infection Market- BY Diseases Figure 7: Global Invasive Fungal Infection Market- By Candidemia and invasive candiasis, By Value (USD Million), 2014-2024 Figure 8: Global Invasive Fungal Infection Market- By Intra-abdominal Candiasis (Candida Peritonitis), By Value (USD Million), 2014-2024 Figure 9: Global Invasive Fungal Infection Market- By Cryptococcal Meningitis , By Value (USD Million), 2014-2024 Figure 10: Global Invasive Fungal Infection Market- By Histoplasmosis Disseminated, By Value (USD Million), 2014-2024 Figure 11: Global Invasive Fungal Infection Market- By Histoplasmosis acute pulmonary, By Value (USD Million), 2014-2024 Figure 12: Global Invasive Fungal Infection Market- By Invasive Aspergillosis, By Value (USD Million), 2014-2024 Figure 13: Global Invasive Fungal Infection Market- By Invasive Rhinosinusitis, By Value (USD Million), 2014-2024 Figure 14: Global Invasive Fungal Infection Market- By Mucormycosis, By Value (USD Million), 2014-2024 Figure 15: Global Invasive Fungal Infection Market- By Pneumocystis Pneumonia, By Value (USD Million), 2014-2024 Figure 16: Global Invasive Fungal Infection Market- By Others, By Value (USD Million), 2014-2024 Figure 17: Competitive Scenario of Global Invasive Fungal Infection- By Region Figure 18: North America Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 19: North America Prevalence of HIV, (%), 2013–2017 Figure 20: North America Deaths by HIV, (%), 2013–2017 Figure 21: North America Prevalence of Neoplasms (%), 2013–2017 Figure 22: North America Prevalence of Tuberculosis (%), 2012–2017 Figure 23: North America Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 24: North America Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 25: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year-2024) Figure 26: Competitive Scenario of North America Invasive Fungal Infection- By Country Figure 27: United States Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 28: US Prevalence of HIV, (%), 2013–2017 Figure 29: US Deaths by HIV, (%), 2013–2017 Figure 30: US Prevalence of Neoplasms (%), 2014–2016 Figure 31: US Prevalence of Tuberculosis (%), 2012–2017 Figure 32: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 33: United States Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 34: Canada Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 35: Canada Prevalence of HIV, (%), 2013–2017 Figure 36: Canada Deaths by HIV, (%), 2013–2017 Figure 37: Canada Prevalence of Neoplasms (%), 2014–2016 Figure 38: Canada Prevalence of Tuberculosis (%), 2012–2017) Figure 39: Canada Invasive Fungal Infection Market- By Diseases(USD Million), 2014-2024 Figure 40: Canada Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 41: Market Opportunity Chart of Europe Invasive Fungal Infection Market - By Country, By Value (Year 2024) Figure 42: Competitive Scenario of Europe Invasive Fungal Infection – By Country Figure 43: Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 44: Europe Prevalence of HIV, (%), 2013–2017 Figure 45: Europe Deaths by HIV, (%), 2013–2017 Figure 46: Europe Prevalence of Neoplasms (%), 2013–2017 Figure 47: Europe Prevalence of Tuberculosis (%), 2012–2017 Figure 48: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 49: Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 50: Germany Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 51: Germany Prevalence of HIV, (%), 2013–2017 Figure 52: Germany Deaths by HIV, (%), 2013–2017) Figure 53: Germany Prevalence of Neoplasms (%), 2013–2017 Figure 54: Germany Prevalence of Tuberculosis (%), 2012–2017 Figure 55: Germany Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 56: Germany Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 57: France Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 58: France Prevalence of HIV, (%), 2013–2017 Figure 59: France Deaths by HIV, (%), 2013–2017 Figure 60: France Prevalence of Neoplasms (%), 2013–2017 Figure 61: France Prevalence of Tuberculosis (%), 2012–2017 Figure 62: France Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 63: France Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 64: United Kingdom Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 65: UK Prevalence of HIV, (%), 2013–2017 Figure 66: UK Deaths by HIV, (%), 2013–2017 Figure 67: UK Prevalence of Neoplasms (%), 2013–2017 Figure 68: UK Prevalence of Tuberculosis (%), 2012–2017 Figure 69: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 70: United Kingdom Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 71: Spain Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 72: Spain Prevalence of HIV, (%), 2013–2017 Figure 73: Spain Deaths by HIV, (%), 2013–2017 Figure 74: Spain Prevalence of Neoplasms (%), 2013–2017 Figure 75: Spain Prevalence of Tuberculosis (%), 2012–2017 Figure 76: Spain Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 77: Spain Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 78: Rest of Europe Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 79: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 80: Rest of Europe Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 81: Market Opportunity Chart of APAC Invasive Fungal Infection Market – By Country, By Value Figure 82: Competitive Scenario of APAC Invasive Fungal Infection – By Country Figure 83: APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 84: Asia Prevalence of HIV, (%), 2013–2017 Figure 85: Asia Deaths by HIV, (%), 2013–2017 Figure 86: Asia Prevalence of Neoplasms (%), 2013–2017 Figure 87: Asia Prevalence of Tuberculosis (%), 2012–2017 Figure 88: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 89: APAC Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 90: China Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 91: China Prevalence of HIV, (%), 2013–2017 Figure 92: China Deaths by HIV, (%), 2013–2017 Figure 93: China Prevalence of Neoplasms (%), 2013–2017 Figure 94: China Prevalence of Tuberculosis (%), 2012–2017 Figure 95: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 96: China Invasive Fungal Infection Market- By Diseases, By Value (USD Million), 2014-2024 Figure 97: South Korea Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 98: South Korea Prevalence of HIV, (%), 2013–2017 Figure 99: South Korea Deaths by HIV, (%), 2013–2017 Figure 100: South Korea Prevalence of Neoplasms (%), 2013–2017 Figure 101: South Korea Prevalence of Tuberculosis (%), 2012–2017 Figure 102: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 103: South Korea Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 104: Japan Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 105: Japan Prevalence of HIV, (%), 2013–2017 Figure 106: Japan Incidence of HIV, (%), 2013–2017 Figure 107: Japan Prevalence of Neoplasms (%), 2013–2017 Figure 108: Japan Prevalence of Tuberculosis (%), 2012–2017 Figure 109: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 110: Japan Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 111: India Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 112: India Prevalence of HIV, (%), 2013–2017 Figure 113: India Incidence of HIV, (%), 2013–2017 Figure 114: India Prevalence of Neoplasms (%), 2013–2017 Figure 115: India Prevalence of Tuberculosis (%), 2012–2017 Figure 116: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 117: India Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 118: Rest of APAC Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 119: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 120: Rest of APAC Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 121: Market Opportunity Chart of North America Invasive Fungal Infection Market - By Country, By Value (Year 2024) Figure 122: Competitive Scenario of Rest of the World Invasive Fungal Infection – By Country Figure 123: Rest of the World Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 124: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 125: ROW Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 126: Brazil Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 127: Brazil Prevalence of HIV, (%), 2013–2017 Figure 128: Brazil deaths of HIV, (%), 2013–2017 Figure 129: Brazil Prevalence of Neoplasms (%), 2013–2017 Figure 130: Brazil Prevalence of Tuberculosis (%), 2012–2017 Figure 131: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 132: Brazil Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 133: Egypt Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 134: Egypt Prevalence of HIV, (%), 2013–2017 Figure 135: Egypt Incidence of HIV, (%), 2013–2017 Figure 136: Egypt Prevalence of Neoplasms (%), 2013–2017 Figure 137: Egypt Prevalence of Tuberculosis (%), 2012–2017 Figure 138: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 139: Egypt Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 140: Rest of the Countries Invasive Fungal Infection Market Size, By Value, 2014-2024 (USD Million) Figure 141: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 142: Rest of the Countries Invasive Fungal Infection Market, By Diseases, By Value (USD Million), 2014-2024 Figure 143: Market Attractiveness Chart of Global Invasive Fungal Infection Market - By Diseases (Year-2024) Figure 144: Market Attractiveness Chart of Global Invasive Fungal Infection Market – By Region, By Value, (Year-204) Figure 145: Competitive Positions of Invasive Fungal Infection Companies (2018) Figure 146: Cidara Therapeutics, Research and Development 2016-2018 (In USD Million) Figure 147: Cidara Therapeutics, Research and Development By Product Category, 2018 (In %) Figure 148: Basilea Revenue, 2014-2018 (In USD Billion) Figure 149: Basilea Revenue, By Region, 2017 (In %) Figure 150: Basilea Revenue, By Region, 2018 (In %) Figure 151: Pfizer Revenue, 2014 - 2018 (In USD Billion) Figure 152: Pfizer Sales Revenue, By Region, 2017 (In %) Figure 153: Pfizer Sales Revenue, By Region, 2018 (In %) Figure 154: Pfizer Revenue, By Business Segment, 2017, 2018 (In USD Million) Figure 155: Pfizer Revenue, By IH Segment, By Region 2018 (In %) Figure 156: Pfizer Revenue, By EH Segment, By Region 2018 (In %) Figure 157: GSK, Turnover, 2014 - 2018 (In USD Billion) Figure 158: GSK, Turnover, By Segments, 2017 (In %) Figure 159: GSK, Turnover, By Segments, 2018 (In %) Figure 160: GSK, Turnover, By Geographic Region, 2017 (In %) Figure 161: GSK, Turnover, By Geographic Region, 2018 (In %) Figure 162: Bayer AG, Sales Revenue, 2014 - 2018 (In USD Million) Figure 163: Bayer AG, Net Sales Revenue, By Region, 2017 (In %) Figure 164: Bayer AG, Net Sales Revenue, By Region, 2018 (In %) Figure 165: Abbott Net Income, 2014 - 2018 (In USD Million) Figure 166: Abbott Sales Revenue, By Business Segment, 2017 (In %) Figure 167: Abbott Sales Revenue, By Business Segment, 2018 (In %) Figure 168: Abbott Sales, By Geographic Region, 2017 (In %) Figure 169: Abbott Sales, By Geographic Region, 2018 (In %) Figure 170: Merck & Co, Sales, 2014 - 2018 (In USD Million) Figure 171: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2017 (In %) Figure 172: Merck & Co, Sales Revenue, By Business Segment, Hospital Acute Care 2018 (In %) Figure 173: Merck & Co, Sales, By Geographic Region, 2017 (In %) Figure 174: Merck & Co, Sales, By Geographic Region, 2018 (In %) Figure 174: Astellas Pharma Inc., Sales, 2014 - 2018 (In USD Billion) Figure 176: Astellas Pharma Inc., Sales Revenue, By Product, 2018 (In USD Billion) Figure 177: Astellas Pharma Inc., Sales Revenue, By Product, 2019 (In USD Billion) Figure 178: Astellas Pharma Inc. , Sales, By Geographic Region, 2017 (In %) Figure 179: Astellas Pharma Inc. , Sales, By Geographic Region, 2018 (In %) Figure 180: SCYNEXIS Inc., Revenue, 2014 - 2018 (In USD Thousands) List of Tables Table A Prominent Invasive Fungal Infection Companies Operated in North America Market Table B Prominent Invasive Fungal Infection Companies Operated in Europe Market Table C Prominent Invasive Fungal Infection Companies Operated in APAC Market

Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G – The Rare Fungal Disease Company, Scynexis Inc